RVMD Latest Headlines

Revolution Medicines rival Erasca falls after early-stage trial data for cancer therapy

at seekingalpha.com (Tue, 28-Apr 7:27 AM)

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Revolution Medicines (RVMD) and Erasca (ERAS)

at www.tipranks.com (Tue, 28-Apr 6:50 AM)

Summit Therapeutics leads all large-cap healthcare stocks in YoY CapEx growth

at seekingalpha.com (Tue, 28-Apr 6:43 AM)

Mizuho Securities Keeps Their Buy Rating on Revolution Medicines (RVMD)

at www.tipranks.com (Sun, 26-Apr 8:19 AM)

Stifel Nicolaus Remains a Buy on Revolution Medicines (RVMD)

at www.tipranks.com (Thu, 23-Apr 10:36 AM)

Guggenheim Remains a Buy on Revolution Medicines (RVMD)

at www.tipranks.com (Thu, 23-Apr 7:21 AM)

Revolution Medicines Raises $2 Billion Through Upsized Stock and Convertible Note Offerings—Key Details and Implications

Market Chameleon (Wed, 15-Apr 8:55 AM)

Revolution Medicines Unveils $1 Billion Capital Raise via Dual Offerings—What’s Next for Its RAS-Targeted Pipeline?

Market Chameleon (Tue, 14-Apr 11:45 AM)

Daraxonrasib’s Breakthrough in Pancreatic Cancer: Revolution Medicines’ Phase 3 Trial Shows Median Survival Doubled

Market Chameleon (Mon, 13-Apr 11:53 AM)

Daraxonrasib Delivers Unmatched Overall Survival in Metastatic Pancreatic Cancer: Pivotal Phase 3 Results Redefine Treatment Possibilities

Market Chameleon (Mon, 13-Apr 8:23 AM)